학술논문

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML
Document Type
Article
Source
In: Blood. (Blood, 11 April 2024, 143(15):1513-1527)
Subject
Language
English
ISSN
15280020
00064971